At #Tandem26: Dr. Steve Grupp chairs the Meet-the-Professor session re: obstacles in commercial roll-out, development and access in ex-vivo #genetherapy. @ASTCT @CIBMTR

Have you made a breakthrough in HCT, cellular or gene therapy? Showcase your work at #Tandem26 & discuss your findings with experts from around the globe. 🌍 Submit your abstract today! @CIBMTR 📅 Deadline: October 9, 2025 🔗 ow.ly/wyrJ50WMqJY

I am deeply honored and humbled to have received the 2025 Merkin Prize in Biomedical Technology along with my long term mentor and colleague Carl June, and Isabelle Rivière, and Michel Sadelain. Innovation and translation of CAR T cell therapies first to clinical trials and then to regulatory approval and commercialization is the collaborative work of many people at many centers. We recognize the importance of that collaboration and the participation of patient volunteers in clinical trials. Without them and faith in science (and NIH, philanthropic, and industry funding), we would not be able to bring new therapies to patients. @PennMedicine @PennCancer @columbiacancer @broadinstitute broadinstitute.org/news/2025…

Today the University of Michigan is ending implementation of DEI. We are eliminating programs, eliminating affiliated staff and ending the DEI 2.0 strategy. Late last year we ended the use of diversity statements in faculty hiring. This is now expanded university wide and statements related to a person’s identity or commitment to DEI will no longer be solicited or considered in admissions, hiring, promotion, awards or reviews for faculty and staff. Savings from these programs will be used to support making Michigan more affordable for our students and families through expansion of the Go Blue Guarantee to family incomes of $125,000 or less and other student facing supports. We are eliminating bureaucratic overspending and making Michigan more accessible. I will continue to push for even greater financial support for talented students with financial need. The total cost of attendance at UM goes far beyond tuition when you consider the high costs of housing, transportation, food and other necessities. I will be working in the future to address these costs for our students who need the most help. Ending DEI programs will also allow us to better expand diversity of thought and free speech on our campus. The end of litmus test hiring and curtailment of speech stops now. People from all walks of life representing a variety of ideologies will be welcome at Michigan. As we move forward with creation of the Institute on Civil Discourse, I look forward to hosting a variety of perspectives on campus. Today’s announcement follows a number of policy and process changes that are making our campus safer and stronger as a place of learning and academic excellence. I’m honored to be a leader at this amazing institution.

This is a serious measles outbreak in Texas. The measles vaccine has been proven safe & effective since 1963.

Brilliant strategy in this litigation over the Trump admin’s research gutting policy on paying NIH grants: Any relief the court orders only affects the 22 states that have sued, predominately blue states, putting the squeeze on GOP states to pressure the admin to rescind the policy.

Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above what many major foundations allow and much lower than the 60%+ that some institutions charge the government today. This change will save more than $4B a year effective immediately.

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies - the @PennMedicine experience -38 gene engineered T cell therapy trials targeting HIV-1 or cancer -783 pts, >2,200 pt yrs of observation -Gammaretroviral or lentiviral vectors -Secondary malignancies in 18 pts (2.3%), median onset 1.94 years (range 51 days to 14 yrs). Solid tumors were most frequent -No evidence of insertional mutagenesis or high-level CAR marking observed -No T cell malignancies that could be attributed to the cell therapy @NatureMedicine #celltherapy #genetherapy #Immunotherapy nature.com/articles/s41591-0…